Efedrin Abboxia
Ephedrine Injection for Treating Low Blood Pressure During Anaesthesia
Quick Facts About Efedrin Abboxia
Key Takeaways
- Efedrin Abboxia is a hospital-only injection used to treat dangerously low blood pressure during spinal, epidural, and general anaesthesia.
- It works as a mixed sympathomimetic, stimulating both alpha and beta adrenergic receptors to increase heart rate, cardiac output, and blood pressure.
- Commonly used during caesarean sections to prevent maternal hypotension from spinal anaesthesia, though phenylephrine is increasingly preferred as first-line.
- Tell your anaesthetist about all medications you take, especially MAO inhibitors (risk of hypertensive crisis), tricyclic antidepressants, and beta-blockers.
- Common side effects include increased heart rate, anxiety, nausea, and elevated blood pressure; these are usually short-lived and resolve after the drug wears off.
What Is Efedrin Abboxia and What Is It Used For?
Efedrin Abboxia contains the active substance ephedrine hydrochloride, a sympathomimetic amine that has been used in clinical medicine for over a century. Ephedrine is classified as a mixed-acting sympathomimetic because it exerts its effects both directly, by binding to alpha- and beta-adrenergic receptors, and indirectly, by stimulating the release of noradrenaline (norepinephrine) from sympathetic nerve terminals. This dual mechanism produces a reliable increase in blood pressure, heart rate, and cardiac output.
The primary clinical indication for Efedrin Abboxia is the treatment and prevention of hypotension during anaesthesia. When patients undergo surgery under spinal (subarachnoid), epidural, or general anaesthesia, the anaesthetic agents can cause significant drops in blood pressure by reducing vascular tone, cardiac output, or both. If left untreated, severe hypotension during surgery can compromise blood flow to vital organs, including the brain, kidneys, and heart, potentially leading to serious complications.
Ephedrine has a particularly important role in obstetric anaesthesia. During caesarean sections performed under spinal anaesthesia, maternal hypotension is extremely common, occurring in up to 70–80% of cases. Rapid treatment is essential to maintain adequate blood flow to both the mother and the fetus. Ephedrine has traditionally been the vasopressor of choice in this setting because of its ability to maintain uteroplacental blood flow while raising maternal blood pressure, although more recent evidence has led to an increased use of phenylephrine as a first-line agent.
Efedrin Abboxia is available in three concentrations to suit different clinical needs: a 3 mg/ml pre-filled syringe for convenient use in emergency settings, a 5 mg/ml solution in 5 ml and 10 ml ampoules for standard dosing, and a 50 mg/ml concentrated solution in 1 ml ampoules that must be diluted before use. The choice of formulation depends on the clinical situation, the required dose, and institutional protocols.
It is important to understand that Efedrin Abboxia is exclusively a hospital-use medication. It is not available for self-administration and should only be given by healthcare professionals with appropriate training and experience in managing blood pressure during anaesthesia and surgical procedures.
What Should You Know Before Receiving Efedrin Abboxia?
Although Efedrin Abboxia is administered by healthcare professionals in a controlled hospital environment, there are several important medical conditions and medication interactions that your anaesthetist must be aware of before this drug is used. Open communication about your medical history is crucial for safe administration.
Contraindications
Efedrin Abboxia must not be used if you have a known allergy (hypersensitivity) to ephedrine hydrochloride or any of the other ingredients in the formulation. Allergic reactions to ephedrine are rare but can include skin rash, itching, swelling, or in severe cases anaphylaxis. If you have ever experienced an allergic reaction to ephedrine or a structurally related sympathomimetic amine, you should inform your anaesthetist immediately.
Warnings and Precautions
Your anaesthetist should exercise particular caution when using ephedrine if you have any of the following conditions:
- Hypertension (high blood pressure): Ephedrine raises blood pressure, which could be dangerous in patients who already have elevated levels. Careful dose titration and continuous blood pressure monitoring are essential.
- Heart disease or cardiovascular problems: This includes coronary artery disease, angina pectoris, heart failure, and arrhythmias. Ephedrine increases heart rate and myocardial oxygen demand, which may worsen these conditions.
- Diabetes mellitus: Ephedrine can alter blood glucose levels through its sympathomimetic effects, potentially making glycaemic control more difficult during and after surgery.
- Hyperthyroidism (overactive thyroid): Patients with hyperthyroidism have increased sensitivity to sympathomimetic amines, and the cardiovascular effects of ephedrine may be exaggerated.
- Closed-angle glaucoma: Ephedrine can cause pupil dilation (mydriasis), which may precipitate an acute angle-closure attack in susceptible individuals.
- Prostatic hyperplasia (enlarged prostate): Ephedrine stimulates alpha-receptors in the bladder neck and prostate, which can worsen urinary obstruction and potentially cause acute urinary retention.
- Severely impaired kidney function: Renal impairment may affect the clearance of ephedrine, potentially prolonging its duration of action and increasing the risk of adverse effects.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before receiving this medication.
Pregnancy: Ephedrine can cross the placenta and may cause increased fetal heart rate (tachycardia). It should not be given during pregnancy unless the physician determines that the potential benefits outweigh the risks. However, ephedrine is commonly used during caesarean section delivery to prevent or treat maternal hypotension caused by spinal anaesthesia. In this specific context, the benefits of maintaining adequate maternal blood pressure and uteroplacental perfusion generally justify its use, and it has a long track record of safety in obstetric anaesthesia.
Breastfeeding: Ephedrine may pass into breast milk. If you have received this medication, your doctor may advise you to avoid breastfeeding for at least two days after administration to minimise any potential exposure to your infant.
How Does Efedrin Abboxia Interact with Other Drugs?
Ephedrine interacts with a wide range of medications, which is particularly important in the perioperative setting where patients may be receiving multiple drugs simultaneously. Your anaesthetist will carefully review your medication list and adjust the anaesthetic plan accordingly. The most clinically significant interactions are outlined below.
Major Interactions
Other drugs with significant interactions include halogenated volatile anaesthetics (such as sevoflurane, desflurane, and isoflurane), which sensitise the heart to the arrhythmogenic effects of sympathomimetic amines. When ephedrine is used concurrently with these agents, there is an increased risk of ventricular arrhythmias. Anaesthetists are well aware of this interaction and adjust doses accordingly.
Tricyclic antidepressants (such as amitriptyline, clomipramine, and nortriptyline) inhibit the neuronal reuptake of noradrenaline, which can potentiate the pressor effects of ephedrine. Similarly, serotonin-noradrenaline reuptake inhibitors (SNRIs) such as venlafaxine, duloxetine, and reboxetine may enhance ephedrine’s cardiovascular effects.
Moderate Interactions
| Drug / Drug Class | Interaction Effect | Clinical Significance |
|---|---|---|
| Phenylephrine, pseudoephedrine, phenylpropanolamine | Additive sympathomimetic effects; excessive blood pressure elevation | High |
| Methylphenidate | Enhanced cardiovascular stimulation | Moderate |
| Cardiac glycosides (e.g., digoxin) | Increased risk of cardiac arrhythmias | High |
| Quinidine | Increased risk of ventricular arrhythmias | High |
| Clonidine, guanethidine | Reduced antihypertensive efficacy; risk of rebound hypertension | Moderate |
| Alpha- and beta-blockers | Altered haemodynamic response; unpredictable blood pressure changes | Moderate |
| Theophylline | Enhanced central nervous system stimulation and cardiovascular effects | Moderate |
| Corticosteroids (e.g., dexamethasone) | Increased risk of hypokalaemia (low potassium) | Moderate |
| Linezolid (antibiotic) | MAO-inhibiting properties; risk of hypertensive response | High |
| Oxytocin | Additive cardiovascular effects during obstetric procedures | Moderate |
| Levodopa, bromocriptine (Parkinson's drugs) | Altered dopaminergic and sympathomimetic balance; arrhythmia risk | Moderate |
| Entacapone, tolcapone (COMT inhibitors) | Reduced catecholamine metabolism; enhanced pressor response | Moderate |
It is essential that you provide your anaesthetist with a complete and accurate list of all medications you are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and recreational substances. Some interactions may require dose adjustments, alternative vasopressor choices, or additional monitoring during the perioperative period.
What Is the Correct Dosage of Efedrin Abboxia?
Efedrin Abboxia is exclusively administered by qualified healthcare professionals—typically anaesthetists, anaesthetic nurses, or other trained personnel—in monitored clinical environments. The dosage is individualised based on the patient's clinical response, and continuous monitoring of blood pressure and heart rate is mandatory throughout treatment.
Adults
Standard Adult Dosing
The typical approach is to administer ephedrine in small, incremental intravenous bolus doses of 3–6 mg, repeated as needed every 3–5 minutes until the desired blood pressure is achieved. The total cumulative dose rarely exceeds 30 mg in a single procedure. For obstetric anaesthesia, bolus doses of 6–12 mg are commonly used, with the higher end of the range being appropriate when rapid correction of hypotension is needed to maintain uteroplacental perfusion.
The onset of action after intravenous administration is rapid, typically within 1–2 minutes, and the duration of effect is approximately 20–60 minutes depending on the dose and the patient’s metabolism.
Children
Paediatric Dosing
In paediatric patients, ephedrine may be used to treat anaesthesia-induced hypotension under specialist supervision. Dosing is weight-based, typically 0.1–0.2 mg/kg per bolus, administered intravenously and titrated to the child's haemodynamic response. Paediatric use should be under the guidance of a paediatric anaesthetist, and continuous monitoring is essential.
Elderly Patients
Geriatric Dosing
Elderly patients may be more sensitive to the cardiovascular effects of ephedrine due to age-related changes in baroreceptor function, reduced cardiac reserve, and altered drug metabolism. Lower initial doses (e.g., 3 mg boluses) and more cautious titration are generally recommended. Close monitoring of heart rate, blood pressure, and cardiac rhythm is particularly important in this population.
Missed Dose
Because Efedrin Abboxia is administered by healthcare professionals in a controlled clinical environment, the concept of a “missed dose” does not apply. The drug is given as needed in response to measured drops in blood pressure, and dosing is guided by real-time haemodynamic monitoring.
Overdose
The risk of overdose in clinical practice is minimised by the fact that ephedrine is given in small incremental doses with continuous haemodynamic monitoring. Anaesthetists titrate each dose based on the patient’s real-time blood pressure and heart rate response, which allows for precise control.
What Are the Side Effects of Efedrin Abboxia?
Like all medicines, Efedrin Abboxia can cause side effects, although not everybody experiences them. The side effects of ephedrine are largely predictable extensions of its sympathomimetic pharmacological action and are typically dose-dependent. Because the drug is administered in a monitored hospital environment, side effects can be detected and managed promptly. The frequency categories below follow the standard European classification system.
Common Side Effects
- Psychiatric: Confusion, anxiety, depression, nervousness, irritability, restlessness
- Nervous system: Insomnia, headache, weakness (asthenia)
- Skin: Sweating (diaphoresis)
- Cardiovascular: High blood pressure (hypertension), increased heart rate (tachycardia, palpitations)
- Respiratory: Difficulty breathing (dyspnoea)
- Gastrointestinal: Nausea, vomiting
Rare Side Effects
- Irregular heartbeat (cardiac arrhythmias)
- Inability to urinate (acute urinary retention)
Not Known (Frequency Cannot Be Estimated)
- Immune system: Hypersensitivity reactions
- Psychiatric: Psychotic states (delusions, hallucinations), fear
- Nervous system: Tremor, increased salivation
- Eye disorders: Episodes of acute angle-closure glaucoma
- Cardiovascular: Angina pectoris, reflex bradycardia (slow heart rate), cardiac arrest, hypotension
- Cerebrovascular: Cerebral haemorrhage (bleeding in the brain)
- Respiratory: Pulmonary oedema (fluid in the lungs)
- Metabolic: Decreased appetite, hypokalaemia (low potassium), altered blood glucose levels
Most of the common side effects, such as increased heart rate and elevated blood pressure, are temporary and resolve as the drug is metabolised and its effects diminish. In a monitored perioperative setting, these effects are continuously tracked, and the anaesthetist can intervene rapidly if any concerning changes are observed. If you experience any unusual or persistent symptoms after receiving ephedrine, inform your healthcare team immediately.
How Should Efedrin Abboxia Be Stored?
As Efedrin Abboxia is a hospital-use medication, it is stored and managed by the hospital pharmacy department under controlled conditions. However, the following storage guidelines apply:
- Keep this medicine out of sight and reach of children.
- Do not use this medicine after the expiry date stated on the label and carton after “EXP”. The expiry date refers to the last day of the stated month.
- Store according to the temperature conditions specified by the manufacturer on the product packaging.
- The solution should be a clear, colourless to slightly yellowish liquid in clear glass ampoules. Do not use if the solution appears discoloured, turbid, or contains particles.
- Each ampoule is for single use only. Any unused solution remaining after the dose has been drawn up must be discarded in accordance with local hospital waste procedures.
The ampoules are colour-coded with ring markings for easy identification: the 5 ml ampoules (5 mg/ml) have blue and green rings, the 10 ml ampoules (5 mg/ml) have green and purple rings, and the 1 ml ampoules (50 mg/ml) have yellow and green rings. This colour-coding system helps prevent medication errors in fast-paced clinical environments.
What Does Efedrin Abboxia Contain?
Efedrin Abboxia 5 mg/ml
The active substance is ephedrine hydrochloride. Each 5 ml ampoule contains 25 mg of ephedrine hydrochloride, and each 10 ml ampoule contains 50 mg of ephedrine hydrochloride. The concentration is 5 mg per millilitre.
The other (inactive) ingredients are:
- Sodium chloride (for isotonicity)
- Sodium citrate (as a buffering agent)
- Citric acid monohydrate (as a pH adjuster)
- Water for injections (as the solvent)
Efedrin Abboxia 50 mg/ml
The active substance is ephedrine hydrochloride. Each 1 ml ampoule contains 50 mg of ephedrine hydrochloride. This is a concentrated formulation that must be diluted before administration.
The only other ingredient is:
- Water for injections
Physical Appearance and Packaging
Efedrin Abboxia is a clear, colourless to slightly yellowish solution supplied in clear glass ampoules. The packaging sizes are:
| Concentration | Ampoule Volume | Total Ephedrine per Ampoule | Pack Size | Colour Code |
|---|---|---|---|---|
| 5 mg/ml | 5 ml | 25 mg | 10 ampoules | Blue & green rings |
| 5 mg/ml | 10 ml | 50 mg | 10 ampoules | Green & purple rings |
| 50 mg/ml | 1 ml | 50 mg | 10 ampoules | Yellow & green rings |
Not all pack sizes may be marketed in every country. The marketing authorisation holder is Abboxia AB, based in Sweden, and the product is manufactured by Laboratoire Renaudin in France.
Frequently Asked Questions About Efedrin Abboxia
Ephedrine and phenylephrine are both vasopressors commonly used to treat hypotension during anaesthesia, but they work through different mechanisms. Ephedrine is a mixed sympathomimetic that stimulates both alpha- and beta-adrenergic receptors, increasing blood pressure, heart rate, and cardiac output simultaneously. Phenylephrine is a selective alpha-1 agonist that raises blood pressure primarily through vasoconstriction, which often triggers a reflex slowing of the heart rate (bradycardia). In obstetric anaesthesia, current international guidelines increasingly recommend phenylephrine as the first-line vasopressor because it is associated with a lower incidence of fetal acidosis. However, ephedrine remains valuable when the heart rate is low or when phenylephrine is unavailable.
While the primary licensed indication for Efedrin Abboxia is the treatment of hypotension during anaesthesia, ephedrine hydrochloride may also be authorised for other uses depending on the country and specific product licence. Historically, oral ephedrine preparations were used to treat nasal congestion, bronchospasm, and obesity, but these uses have largely been replaced by safer and more selective alternatives. In hospital settings, injectable ephedrine may sometimes be used off-label for other causes of acute hypotension. Any off-label use should be guided by current evidence and clinical judgement.
When given intravenously, ephedrine has a very rapid onset of action, typically raising blood pressure within 1 to 2 minutes. The peak effect is usually seen within 2 to 5 minutes. The duration of action varies between 20 and 60 minutes depending on the dose administered and individual patient factors. This rapid onset makes it particularly useful in emergency situations where blood pressure needs to be corrected quickly during surgical procedures.
The 50 mg/ml formulation is a concentrated solution designed to be diluted before administration. It allows hospitals to prepare specific concentrations according to their institutional protocols and clinical needs. This concentrated form is particularly useful when larger total doses may be required or when specific dilution ratios are needed for infusion pumps. It must never be administered undiluted as an intravenous bolus due to the risk of severe cardiovascular effects from a rapid, high-dose injection.
No, ephedrine and pseudoephedrine are related but distinct substances. They are stereoisomers, meaning they share the same chemical formula but have different three-dimensional arrangements. Pseudoephedrine is widely available as an oral decongestant in over-the-counter cold and flu medicines. While both compounds have sympathomimetic properties, pseudoephedrine is primarily used for its decongestant effect on nasal passages, whereas injectable ephedrine (as in Efedrin Abboxia) is a much more potent cardiovascular agent used specifically to treat acute hypotension in clinical settings. The two should not be confused or considered interchangeable.
Yes, tachyphylaxis (a diminished response to repeated doses) is a well-recognised phenomenon with ephedrine. Because a significant portion of ephedrine's effect comes from releasing stored noradrenaline from nerve terminals, repeated doses can deplete these stores, leading to a progressively weaker blood pressure response. This is one reason why anaesthetists typically switch to a direct-acting vasopressor such as phenylephrine or noradrenaline if the initial response to ephedrine is insufficient or waning. Understanding this pharmacological property is important for safe and effective clinical use.
References
- Kee WDN, Khaw KS, Ng FF. Prevention of hypotension during spinal anaesthesia for caesarean delivery: An effective technique using combination phenylephrine infusion and crystalloid cohydration. Anesthesiology. 2005;103(4):744-750.
- Ngan Kee WD, Lee SWY, Ng FF, Tan PE, Khaw KS. Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anaesthesia for cesarean delivery. Anesthesiology. 2015;122(4):736-745.
- Heesen M, Kolhr S, Rossaint R, Straube S. Prophylactic phenylephrine for caesarean section under spinal anaesthesia: systematic review and meta-analysis. Anaesthesia. 2014;69(2):143-165.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Summary of Product Characteristics for ephedrine hydrochloride injection. Accessed January 2026.
- Dyer RA, Reed AR, van Dyk D, et al. Hemodynamic effects of ephedrine, phenylephrine, and the coadministration of phenylephrine with oxytocin during spinal anesthesia for elective cesarean delivery. Anesthesiology. 2009;111(4):753-765.
- Practice Guidelines for Obstetric Anesthesia. American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology. 2016;124(2):270-300.
- National Institute for Health and Care Excellence (NICE). Caesarean birth (NG192). NICE Guidelines. Updated 2023.
- British National Formulary (BNF). Ephedrine hydrochloride. NICE Evidence Services. Accessed January 2026.
- European Society of Anaesthesiology and Intensive Care (ESAIC). Guidelines on perioperative hypotension management. European Journal of Anaesthesiology. 2024;41(1):1-22.
Editorial Team
This article was written by the iMedic Medical Editorial Team, comprising licensed specialist physicians in anaesthesiology, clinical pharmacology, and perioperative medicine. All content is reviewed according to international medical guidelines (WHO, ESA, ASA, NICE) and follows the GRADE evidence framework.